Autologous RNA Cell Therapy- Cartesian LTF-001

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.

Inclusion Criteria

• A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug.
• A participant has provided informed consent for LTF-001.
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.